{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T20:14:55Z","timestamp":1770840895326,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Innovative Clinical Technique of Guangzhou","award":["2019GX04"],"award-info":[{"award-number":["2019GX04"]}]},{"name":"the Innovative Clinical Technique of Guangzhou","award":["No.2023C-GX01"],"award-info":[{"award-number":["No.2023C-GX01"]}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"crossref","award":["2024A03J1021"],"award-info":[{"award-number":["2024A03J1021"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Guangzhou General Science and Technology Project of Health and Family Planning","award":["20241A011012"],"award-info":[{"award-number":["20241A011012"]}]},{"name":"the National Key R&D Program of China","award":["2023YFA1800100"],"award-info":[{"award-number":["2023YFA1800100"]}]},{"name":"Science and Technology Projects in Guangzhou","award":["202201010062"],"award-info":[{"award-number":["202201010062"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03794-8","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:35:09Z","timestamp":1768800909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Refining letermovir prophylaxis strategies and CD4\u2009+\u2009T cell-guided discontinuation in aplastic anemia patients post-allogeneic HSCT: a retrospective analysis"],"prefix":"10.1186","volume":"31","author":[{"given":"Yuling","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjian","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiqing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingfen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LiangLiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"1","key":"3794_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1365-2141.2009.07842.x","volume":"147","author":"JC Marsh","year":"2009","unstructured":"Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43\u201370. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07842.x.","journal-title":"Br J Haematol"},{"issue":"1","key":"3794_CR2","first-page":"78","volume":"91","author":"P Ljungman","year":"2006","unstructured":"Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006;91(1):78\u201383.","journal-title":"Haematologica"},{"issue":"3","key":"3794_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00289-6","volume":"3","author":"ML Green","year":"2016","unstructured":"Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119. https:\/\/doi.org\/10.1016\/S2352-3026(15)00289-6.","journal-title":"Lancet Haematol"},{"issue":"7","key":"3794_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40261-024-01376-w","volume":"44","author":"M Fukuda","year":"2024","unstructured":"Fukuda M, Hattori J, Ohkubo R, et al. Real-world safety and effectiveness of letermovir in patients undergoing allogenic hematopoietic stem cell transplantation: final results of post-marketing surveillance in Japan. Clin Drug Investig. 2024;44(7):527\u201340. https:\/\/doi.org\/10.1007\/s40261-024-01376-w.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"3794_CR5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40121-024-00917-2","volume":"13","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Chen X, Zhou M, et al. Letermovir effectively prevents cytomegalovirus infection in patients with aplastic anemia after hematopoietic stem cell transplantation: a real-world retrospective cohort study. Infect Dis Ther. 2024;13(2):345\u201359. https:\/\/doi.org\/10.1007\/s40121-024-00917-2.","journal-title":"Infect Dis Ther"},{"issue":"5","key":"3794_CR6","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1182\/bloodadvances.2023010735","volume":"8","author":"T Toya","year":"2024","unstructured":"Toya T, Mizuno K, Sakurai M, et al. Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysis. Blood Adv. 2024;8(5):1084\u201393. https:\/\/doi.org\/10.1182\/bloodadvances.2023010735.","journal-title":"Blood Adv"},{"issue":"14","key":"3794_CR7","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1182\/bloodadvances.2023012175","volume":"8","author":"A Sadowska-Klasa","year":"2024","unstructured":"Sadowska-Klasa A, Ozkok S, Xie H, et al. Late cytomegalovirus disease after hematopoietic cell transplantation: significance of novel transplantation techniques. Blood Adv. 2024;8(14):3639\u201351. https:\/\/doi.org\/10.1182\/bloodadvances.2023012175.","journal-title":"Blood Adv"},{"issue":"4","key":"3794_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad169","volume":"10","author":"L Chavaz","year":"2023","unstructured":"Chavaz L, Royston L, Masouridi-Levrat S, et al. CMV infection after letermovir primary prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients. Open Forum Infect Dis. 2023;10(4):ofad169. https:\/\/doi.org\/10.1093\/ofid\/ofad169.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"3794_CR9","doi-asserted-by":"publisher","first-page":"211 e1","DOI":"10.1016\/j.jtct.2022.01.008","volume":"28","author":"E Gabanti","year":"2022","unstructured":"Gabanti E, Borsani O, Colombo AA, et al. Human cytomegalovirus-specific T-cell reconstitution and late-onset cytomegalovirus infection in hematopoietic stem cell transplantation recipients following letermovir prophylaxis. Transplant Cell Ther. 2022;28(4):211 e1-211 e9. https:\/\/doi.org\/10.1016\/j.jtct.2022.01.008.","journal-title":"Transplant Cell Ther"},{"issue":"21","key":"3794_CR10","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1182\/bloodadvances.2021005637","volume":"5","author":"MAV Marzolini","year":"2021","unstructured":"Marzolini MAV, Mehra V, Thomson KJ, et al. Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting. Blood Adv. 2021;5(21):4500\u20133. https:\/\/doi.org\/10.1182\/bloodadvances.2021005637.","journal-title":"Blood Adv"},{"issue":"2","key":"3794_CR11","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","volume":"11","author":"D Russo","year":"2024","unstructured":"Russo D, Schmitt M, Pilorge S, et al. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2024;11(2):e127\u201335. https:\/\/doi.org\/10.1016\/S2352-3026(23)00344-7.","journal-title":"Lancet Haematol"},{"issue":"1","key":"3794_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood.2020009396","volume":"138","author":"D Zamora","year":"2021","unstructured":"Zamora D, Duke ER, Xie H, et al. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. Blood. 2021;138(1):34\u201343. https:\/\/doi.org\/10.1182\/blood.2020009396.","journal-title":"Blood"},{"issue":"2","key":"3794_CR13","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1016\/S2352-3026(23)00368-X","volume":"11","author":"AP Douglas","year":"2024","unstructured":"Douglas AP, Slavin MA. Extended duration of letermovir prophylaxis: how long is long enough? Lancet Haematol. 2024;11(2):e88\u201390. https:\/\/doi.org\/10.1016\/S2352-3026(23)00368-X.","journal-title":"Lancet Haematol"},{"key":"3794_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2023.101936","volume":"81","author":"B Hinman","year":"2023","unstructured":"Hinman B, Cox J, Umoru G, et al. Extended duration letermovir in allogeneic hematopoietic stem cell transplant. Transpl Immunol. 2023;81:101936. https:\/\/doi.org\/10.1016\/j.trim.2023.101936.","journal-title":"Transpl Immunol"},{"key":"3794_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev-med-042921-124739","volume":"74","author":"JL Saullo","year":"2023","unstructured":"Saullo JL, Miller RA. Cytomegalovirus therapy: role of letermovir in prophylaxis and treatment in transplant recipients. Annu Rev Med. 2023;74:89\u2013105. https:\/\/doi.org\/10.1146\/annurev-med-042921-124739.","journal-title":"Annu Rev Med"},{"issue":"2","key":"3794_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.7326\/0003-4819-125-2-199607150-00009","volume":"125","author":"H Masur","year":"1996","unstructured":"Masur H, Whitcup SM, Cartwright C, et al. Advances in the management of AIDS-related cytomegalovirus retinitis. Ann Intern Med. 1996;125(2):126\u201336. https:\/\/doi.org\/10.7326\/0003-4819-125-2-199607150-00009.","journal-title":"Ann Intern Med"},{"issue":"6","key":"3794_CR17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/ICU.0b013e328358ba85","volume":"23","author":"NJ Butler","year":"2012","unstructured":"Butler NJ, Thorne JE. Current status of HIV infection and ocular disease. Curr Opin Ophthalmol. 2012;23(6):517\u201322. https:\/\/doi.org\/10.1097\/ICU.0b013e328358ba85.","journal-title":"Curr Opin Ophthalmol"},{"issue":"9","key":"3794_CR18","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1093\/cid\/cit494","volume":"57","author":"N Ford","year":"2013","unstructured":"Ford N, Shubber Z, Saranchuk P, et al. Burden of HIV-related cytomegalovirus retinitis in resource-limited settings: a systematic review. Clin Infect Dis. 2013;57(9):1351\u201361. https:\/\/doi.org\/10.1093\/cid\/cit494.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"3794_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/cid\/ciae321","volume":"79","author":"P Ljungman","year":"2024","unstructured":"Ljungman P, Chemaly RF, Khawaya F, et al. Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the transplant associated virus infections forum. Clin Infect Dis. 2024;79(3):787\u201394. https:\/\/doi.org\/10.1093\/cid\/ciae321.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"3794_CR20","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/s41409-020-01082-z","volume":"56","author":"Y Mori","year":"2021","unstructured":"Mori Y, Jinnouchi F, Takenaka K, et al. Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data. Bone Marrow Transplant. 2021;56(4):853\u201362. https:\/\/doi.org\/10.1038\/s41409-020-01082-z.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"3794_CR21","doi-asserted-by":"publisher","first-page":"510 e1","DOI":"10.1016\/j.jtct.2022.05.020","volume":"28","author":"LW Liu","year":"2022","unstructured":"Liu LW, Yn A, Gao F, et al. Letermovir discontinuation at day 100 after allogeneic stem cell transplant is associated with increased CMV-related mortality. Transplantation and Cellular Therapy. 2022;28(8):510 e1-510 e9. https:\/\/doi.org\/10.1016\/j.jtct.2022.05.020.","journal-title":"Transplantation and Cellular Therapy"},{"issue":"25","key":"3794_CR22","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1706640.","journal-title":"N Engl J Med"},{"issue":"11","key":"3794_CR23","doi-asserted-by":"publisher","first-page":"1099 e1","DOI":"10.1016\/j.jtct.2024.08.016","volume":"30","author":"X Chen","year":"2024","unstructured":"Chen X, Chen C, Zhou M, et al. Efficacy of a modified post-transplant cyclophosphamide regimen for unrelated donor hematopoietic stem cell transplantation in patients with severe aplastic anemia: a prospective study. Transplantation and Cellular Therapy. 2024;30(11):1099 e1-1099 e10. https:\/\/doi.org\/10.1016\/j.jtct.2024.08.016.","journal-title":"Transplantation and Cellular Therapy"},{"issue":"2","key":"3794_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/sj.bmt.1705699","volume":"40","author":"E Ozdemir","year":"2007","unstructured":"Ozdemir E, Saliba RM, Champlin RE, et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007;40(2):125\u201336. https:\/\/doi.org\/10.1038\/sj.bmt.1705699.","journal-title":"Bone Marrow Transplant"},{"key":"3794_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.900154","volume":"12","author":"W Mo","year":"2022","unstructured":"Mo W, Chen X, Zhang X, et al. The potential association of delayed T lymphocyte reconstitution within six months post-transplantation with the risk of cytomegalovirus retinitis in severe aplastic anemia recipients. Front Cell Infect Microbiol. 2022;12:900154. https:\/\/doi.org\/10.3389\/fcimb.2022.900154.","journal-title":"Front Cell Infect Microbiol"},{"issue":"11","key":"3794_CR26","doi-asserted-by":"publisher","first-page":"1450 e1","DOI":"10.1016\/j.cmi.2023.07.026","volume":"29","author":"E Kampouri","year":"2023","unstructured":"Kampouri E, Zamora D, Kiem ES, et al. Human herpesvirus-6 reactivation and disease after allogeneic haematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis. Clin Microbiol Infect. 2023;29(11):1450 e1-1450 e7. https:\/\/doi.org\/10.1016\/j.cmi.2023.07.026.","journal-title":"Clin Microbiol Infect"},{"key":"3794_CR27","doi-asserted-by":"publisher","unstructured":"Qiu K, Wang X, Liu Z, et al. Targeting\nUSP10\u2013FAK pathway sensitizes BCR-ABL+\nleukemia cells to tyrosine kinase inhibitors. Cell Investigation,\n2025, 1(2):100017. https:\/\/doi.org\/10.1016\/j.clnves.2025.100017","DOI":"10.1016\/j.clnves.2025.100017"},{"key":"3794_CR28","doi-asserted-by":"publisher","unstructured":"Wang P, Cai Q, Peng X, et al.\nIncreased co-expression of CTLA4\/LAG3 predicted\nadverse clinical outcomes in patients with T-cell malignancies.\nCell Investigation, 2025, 1(1):100004. https:\/\/doi.org\/10.1016\/j.clnves.2024.100004","DOI":"10.1016\/j.clnves.2024.100004"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03794-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03794-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03794-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:47:30Z","timestamp":1770839250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-025-03794-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3794"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03794-8","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Guangzhou First People\u2019s Hospital. All participants were provided with written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"285"}}